Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928226 · ClinicalTrials.gov registry record · NA
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00928226: Completed NA study, sponsored by Stanford University.
NCT00928226 is a NA study that has completed, run by Stanford University. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928226, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
Primary Outcome
The maximum-tolerated Dose (MTD) of stereotactic radiosurgery (SRS) was assessed based on the number of dose-limiting toxicities (DLTs). DLT was defined as any treatment-related grade 3, 4, or 5 central nervous system (CNS) radiation morbidity observed within 30 days of radiosurgery. CNS radiation morbidity was further defined as. * 5 = Death * 4 = Serious neurologic impairment such as paralysis, coma, or seizures \> 3/week * 3 = Neurologic findings requiring hospitalization * 2 = Neurologic fi
Interventions
- PROCEDURE Surgical resection
- RADIATION Fractionated Stereotactic Radiosurgery (SRS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-04 |
| Est. Completion | 2019-12 |
| Phase | NA |
What the finished NCT00928226 record still lists
NCT00928226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Surgical resection is the first listed.
NCT00928226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00928226 about?
NCT00928226 is a clinical study titled "Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases". The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
What is the current status of trial NCT00928226?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2009-04. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00928226?
The interventions under investigation include: Surgical resection (PROCEDURE), Fractionated Stereotactic Radiosurgery (SRS) (RADIATION).
Who is sponsoring clinical trial NCT00928226?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00928226's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia